Cantor Fitzgerald Reiterates Overweight on EyePoint Pharmaceuticals, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Jennifer Kim has reiterated an Overweight rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) and maintained a $31 price target.
September 14, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on EyePoint Pharmaceuticals and maintained a $31 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for EyePoint Pharmaceuticals. The maintained price target of $31 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100